A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 77, Issue 2, 2003, Pages 115-123

  Loesch, David M ^a   Asmar, Lina ^b   Canfield, Vikki A ^c   Parker, Gregory A ^c   Hynes, Harry E ^d   Ellis, Peter G ^e   Ferri Jr , William A ^f   Robert, Nicholas J ^g  

^a Oncol/Hematology Associates Inc   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c Cancer Care Associates   (United States)

^d Cancer Center of Kansas   (United States)

^e Oncology Hematology Associates   (United States)

^f Oncology Hematology Associates   (United States)

^g Fairfax Prnc William Hematol O   (United States)

Author keywords

Fluorouracil; Leucovorin; Metastatic breast cancer; Paclitaxel; Therapy; Weekly

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GROWTH FACTOR; PACLITAXEL;

ADULT; AGED; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST ADENOCARCINOMA; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OUTCOMES RESEARCH; OUTPATIENT CARE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037272713     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021384318470     Document Type: Article

References (27)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001
2. Ellis MJ, Hayes DF, Lippman ME: Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast, 2nd edn, Lippincott Williams & Wilkins, Philadelphia, 2000, pp 749-797
3. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67: 801-805, 1993
4. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460, 1998
5. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996
6. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao T-J, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575-2581, 1995
7. Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1993
8. Seidman AD, Reichman BS, Crown JPA, Yao T-J, Cúrrie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S, Norton L: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995
9. Fountzilas G, Athanassiades A, Giannakakis T, Bafaloukos D, Karakousis K, Dombros N, Kosmidis P, Skarlos D: A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32A: 47-51, 1996
10. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A, Valagussa P, Bonadonna G: Paclitaxel in metastatic breast cancer: a trial of two doses by 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169-1175, 1995
11. Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellman S, Canetta R, Friedman MA, Arbuck S: Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13: 2056-2065, 1995
12. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991
13. Seidman AD, Hudis C, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998
14. Perez EA, Irwin DH, Patel R, Vogel CL, Kirshner J: A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 18: 126a, 1999 (abstract)
15. Waintraub SE, Cantwell S, DeVries J: Phase II study to evaluate the efficacy of weekly paclitaxel (WP) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline (A) +/- taxane (T) therapy. Proc Am Soc Clin Oncol 19: 121a, 2000 (abstract)
16. Alvarez AM, Mickiewicz E, Brosio C, Giglio R, Cinat G, Rodger J, Nicolás C: Reinduction of response with weekly Taxol (T) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 18: 165a, 1999 (abstract)
17. Sola C, Lluch A, García-Conde J, Salazar R, García T, Montesinos J, Vera R, Benavides M, Climent MA, Homedo J, Alvarez I, Prósper F, Cortés-Funes H, López López JJ: Phase II study of weekly paclitaxel (P) treatment in recurrent breast cancer after high-dose chemotherapy (HDC). Proc Am Soc Clin Oncol 18: 65a, 1999 (abstract)
18. Mickiewicz E, Alvarez AM, Brosio C, Giglio R, Cinat G, Rodger J, Nicolás C: A promising second line treatment with weekly Taxol (T) in anthracycline recurrent, advanced breast cancer (ABC) patients (PTS). Proc Am Soc Clin Oncol 18: 135a, 1999 (abstract)
19. Breier S, Lebedinsky C, Ayiviri A, Roffé C, Traine G, Cot C, Politi P: Long-term weekly paclitaxel (P) in metastatic breast cancer (MBC). A phase II trial in pretreated patients (pts). Proc Am Soc Clin Oncol 17: 192a, 1998 (abstract)
20. Doroshow JH, Leong L, Margolin K, Flanagan B, Goldberg D, Bertrand M, Akman S, Carr B, Odujinrin O, Newman E: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7: 439-444, 1989
21. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890-899, 1989
22. Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Raschko JW, Somlo G, Blevins C: Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. J Clin Oncol 10: 1278-1283, 1992
23. Grem JL, Nguyen D, Monahan BP, Kao V, Geoffroy FJ: Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 58: 477-486, 1999
24. Nicholson B, Paul D, Shyr Y, Garrett M, Hande KR, Johnson DH: Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilr Cancer Center phase II trial. Semin Oncol 24 (suppl 11): s11-20-s11-23, 1997
25. Klaassen U, Wilke H, Harstrick A, Philippou Pari C, Strumberg D, Neumann K, Eberhardt W, Achterrath W, Lenaz L, Seeber S: Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study. Ann Oncol 9: 45-50, 1998
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
27. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain M, Kearns CM, Schilsky RL: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16: 1811-1819, 1998